Rohit Gosain

Hello and welcome back to the Oncology Brothers podcast.

I'm Rahul Gosain, here with my brother and your co-host, Rohit Gosain.

This past weekend at ESMO 2026 in Madrid, thousands of abstracts were presented.

Close to 40,000 people attended this.

Thanks for joining us.

I'm Rahul Gosain here with my brother and co-host Rohit Gosain, and we are the Oncology Brothers.

In our ongoing Partners in Practice discussion, where we hear from our different team members who are at the forefront of delivering cancer care alongside our physicians.

Today, we're joined by Dr. Rafael Fonseca, a multiple myeloma specialist from Mayo Clinic, Dr. Beth Feynman, a nurse practitioner focusing on myeloma, and Ms. Keri Biller-Reeve, a clinical nurse coordinator working at Sloan Kettering.

So that conversation has changed a bit, but again, we just need more work around

that.

Beth and Rohit, I completely agree.

Physician bias, comfort around these treatment options, and of course, patient preference is what drives this decision.

They happen to be podcasters.

We have Rohit Gosain and Rahul Gosain.

Welcome gentlemen.

First of all, doctors.

Hello, and welcome back to the Oncology Brothers podcast.

I'm Rohit Gosain, alongside my brother and co-host, Rahul Gosain.

In our new series of rapid fire rounds, we have our panelists answer 10 to 12 pinpointed questions from the community colleagues.

This could be a case question around the data or new approvals.

You know, and then also if there's other cytopenias, then maybe you want to think more about a bone marrow biopsy.

I'm gonna reserve the bone marrow biopsy for when I have really done a robust history and physical and done my workup on the periphery, and then only then will I use the marrow if I still can't figure out what's going on.

And Rohit, here your abdominal imaging can also help, right? We're also-

Right

Misty, would you ever consider off-label use of Trilociclib here, or are we better off dose-reducing the regimen or switching to even carboplatin etoposide?

Thank you, Rohit.

This is a really timely and important question.

For patients who are undergoing limited-stage treatment for a cure, it's very important to try to stay on therapy and keep the intensity as much as we can.

Misty, for the same patient here, post-chemo radiation therapy while they're on consolidation durvalumab.

after that six months timeframe where they're still platinum sensitive, if the disease was to progress, would you add platinum etoposide here or move along into the second line that is terlatumab?

This is a great question, Rohit.

And I think this really shows that the era that we know of small cell has really transformed just over the last few years.